90Y-NM600 for Metastatic Cancer

This trial explores a new treatment for individuals with metastatic cancer, aiming to determine if adding a radioactive imaging agent (Y-NM600) can enhance the effectiveness of current cancer drugs and identify the optimal dose. The trial targets those whose cancer continues to spread despite receiving specific immune therapies like Keytruda or Opdivo. Suitable candidates include individuals with metastatic cancers such as lung, liver, or bladder cancer, who have experienced cancer progression on recent scans but are still undergoing their current cancer treatment. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

You can continue taking your current anti-PD-1 or anti-PD-L1 therapy, as well as Ipilimumab or Tremelimumab, during the trial. However, you must stop taking any strong inducers or inhibitors of CYP450 enzymes or drug transporters at least 30 days before the trial and throughout its duration.

Research has shown that 90Y-NM600 has been tested in animals, specifically mice, with promising results. In these studies, mice with certain types of tumors treated with 90Y-NM600 experienced tumor shrinkage and lived longer. Importantly, no major safety concerns emerged in these animal studies.

However, this trial is in an early stage, meaning limited information exists about human reactions to the treatment. Early-stage trials like this one focus on determining the right dose and assessing safety for humans. Since 90Y-NM600 is not yet approved for human use, participants will help researchers learn about its safety in humans.

Researchers are excited about 90Y-NM600 for metastatic cancer because it employs a novel approach using a radioactive isotope, yttrium-90, that targets cancer cells more precisely. Unlike traditional chemotherapy, which can affect both healthy and cancerous cells, 90Y-NM600 is designed to deliver radiation directly to tumors, potentially reducing side effects. The treatment also offers flexibility in dosing, with different levels being tested to find the most effective and safe dose. This targeted radiotherapy could lead to better outcomes for patients with metastatic cancer by focusing on the disease more accurately and reducing harm to healthy tissues.

Research has shown that 90Y-NM600 can be effective against certain tumors. In studies with mice, this treatment stopped tumors from growing and increased survival, particularly in a type of non-Hodgkin lymphoma called T-cell NHL. It even showed potential for long-term remission, suggesting the body might learn to fight the cancer independently. The treatment targets cancer cells with radiation, making the tumor environment less suitable for growth. Although results in prostate cancer were less encouraging, the treatment might still aid patients receiving immunotherapy by boosting their immune system's response to tumors. Participants in this trial will receive different dosages of 90Y-NM600 to evaluate its safety and effectiveness.¹²⁵⁶⁷